- 1、本文档共6页,可阅读全部内容。
- 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
膀胱癌有利文章
Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
Carlo Piccinni, PHD , Domenico Motola, PHD
Diabetes Care June 2011 vol. 34 no. 6 1369-1371
Abstract
OBJECTIVE To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications.
RESEARCH DESIGN AND METHODS Case/noncase bladder cancer reports associated with antidiabetic drug use were retrieved from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) between 2004 and 2009 and analyzed by the reporting odds ratio (ROR).
RESULTS Ninety-three reports of bladder cancer were retrieved, corresponding to 138 drug-reaction pairs (pioglitazone, 31; insulin, 29; metformin, 25; glimepiride, 13; exenatide, 8; others, 22). ROR was indicative of a definite risk for pioglitazone (4.30 [95% CI 2.82–6.52]), and a much weaker risk for gliclazide and acarbose, with very few cases being treated with these two drugs (6 and 4, respectively).
CONCLUSIONS In agreement with preclinical and clinical studies, AERS analysis is consistent with an association between pioglitazone and bladder cancer. This issueneeds constant epidemiologic surveillance and urgent definition by more specific studies.
A link between pioglitazone and bladder cancer first appeared in preclinical studies and was first reported on the U.S. pioglitazone label in 1999, but experimental studies recently suggested that it might be a rat-specific phenomenon (1). In the large PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) study, 14 bladder cancers occurred in the pioglitazone arm (0.5%) versus 6 in the placebo arm (0.2%) (2,3), and in September 2010, the U.S. Food and Drug Administration (FDA) announced an ongoing investigation on the possible risk in humans (4). Accordingly, the drug manufacturer is conducting a 10-year observational study to address the long-term risk of bladder ca
您可能关注的文档
最近下载
- 二单元民族学的源流理论视角及研究方法.ppt
- 我国政务B站号传播效果现状及影响因素研究.docx VIP
- DB15T 3962.7-2025绿色矿山建设规范 第7部分:水泥灰岩行业.pdf VIP
- 高中语文统编版下册《祝福》、《林教头风雪山神庙》联读 (1).pptx
- 一种D-手性肌醇的制备方法.pdf VIP
- 辽宁省2024学年度普通高中学业水平合格性考试化学试题及答案.docx
- 跨境电商平台的财务管理策略.docx VIP
- 合规性评价报告(2025年).docx
- 【英语试卷+答案】2024年宁德市4月初中毕业班质量检测.pdf VIP
- 2025云南省红河州开远市纪委监委招聘合同制辅助人员(8人)笔试备考试题及答案解析.docx VIP
文档评论(0)